Craft
  • Home
  •  / Regulus Therapeutics
Regulus Therapeutics

Regulus Therapeutics

Patents Issued

300

FY, 2016

Revenue

$10 M

FY, 2020

Market Capitalization

$258.4 M

2022-09-22

Regulus Therapeutics Summary

Company summary

Overview
Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection, and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy.Regulus is also advancing several programs toward clinical development in renal, hepatic and central nervous systems diseases, both independently and with our strategic alliance partners.
Type
Public
Founded
2007
HQ
San Diego, CA, US | view all locations
Website
http://regulusrx.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Cris Calsada, Chief Financial Officer

  • Stelios Papadopoulos, Director

    • Christopher Aker

      Christopher Aker, Senior Vice President and General Counsel

    • David Baltimore, Director

      Operating MetricsView all

      Patents Issued

      300

      FY, 2016

      LocationsView all

      1 location detected

      • San Diego, CA HQ

        United States

        4224 Campus Point Ct Suite 210

      Regulus Therapeutics Financials

      Summary financials

      Net income (Q2, 2022)
      ($7.3M)
      Cash (Q2, 2022)
      $35.1M
      EBIT (Q2, 2022)
      ($7.2M)
      Enterprise value
      $271.5M

      Footer menu